JP2005501006A - 非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法 - Google Patents

非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法 Download PDF

Info

Publication number
JP2005501006A
JP2005501006A JP2003501405A JP2003501405A JP2005501006A JP 2005501006 A JP2005501006 A JP 2005501006A JP 2003501405 A JP2003501405 A JP 2003501405A JP 2003501405 A JP2003501405 A JP 2003501405A JP 2005501006 A JP2005501006 A JP 2005501006A
Authority
JP
Japan
Prior art keywords
unsubstituted
compound
heteroaryl
heterocycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003501405A
Other languages
English (en)
Japanese (ja)
Inventor
ティー． サン，エリック
ビー． アンダーソン，マーク
リン アンドレス，ケンナ
クリストファー クリスティー，ランス
チュイ ド，キュイェン−キュイェン
フェン，ジュン
ゴーツェン，トーマス
ホン，ユーフェン
アナトリーフナ クライノフ，ユージーニア
リ，ハイタオ
ロバート． ルーティン，デイビッド
ディー． パドレス，ジェネビーブ
ピー． パタク，ベド
ジャガス ラジャパクセ，ランジャン
シャッケルフォード，スコット
バレンチュラ トンプキンス，アイリーン
ケネス トルーズデール，ラリー
バジル，ハレシュ
Original Assignee
アグロン・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アグロン・ファーマシューティカルズ・インコーポレーテッド filed Critical アグロン・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2005501006A publication Critical patent/JP2005501006A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2003501405A 2001-06-06 2002-06-05 非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法 Withdrawn JP2005501006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29581201P 2001-06-06 2001-06-06
US30186801P 2001-06-29 2001-06-29
PCT/US2002/017846 WO2002098363A2 (fr) 2001-06-06 2002-06-05 Agents gnrh non peptidiques, compositions pharmaceutiques et methodes d'utilisation de ces dernieres, procedes de preparation de ces composes et de leurs intermediaires

Publications (1)

Publication Number Publication Date
JP2005501006A true JP2005501006A (ja) 2005-01-13

Family

ID=26969346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501405A Withdrawn JP2005501006A (ja) 2001-06-06 2002-06-05 非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法

Country Status (7)

Country Link
EP (1) EP1401427A4 (fr)
JP (1) JP2005501006A (fr)
AU (1) AU2002312348A1 (fr)
BR (1) BR0210191A (fr)
CA (1) CA2449843A1 (fr)
MX (1) MXPA03011002A (fr)
WO (1) WO2002098363A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531368A (ja) * 2012-09-28 2015-11-02 アビバックス 新規抗浸潤化合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
BR0312123A (pt) * 2002-06-13 2005-03-29 Pfizer Agentes de gnrh não peptìdicos, composições farmacêuticas e métodos para o seu uso
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
EP1541549A1 (fr) * 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Dérivés tricycliques d'hydroxamate et de benzamide, compositions et methodes
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102329234B (zh) * 2011-06-24 2013-11-06 灌南伊斯特化工有限公司 一种间硝基苯甲醛的生产工艺
US20160058895A1 (en) * 2013-04-19 2016-03-03 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
CN108905641B (zh) * 2018-08-01 2020-04-28 湖南七纬科技有限公司 一种纳滤膜及其制备方法
CN114105775A (zh) * 2021-11-30 2022-03-01 武汉工程大学 一种带有末端双键的取代碘苯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
US6218426B1 (en) * 1998-03-05 2001-04-17 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents
AU759310B2 (en) * 1998-08-20 2003-04-10 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents, methods and intermediates for their preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531368A (ja) * 2012-09-28 2015-11-02 アビバックス 新規抗浸潤化合物

Also Published As

Publication number Publication date
CA2449843A1 (fr) 2002-12-12
EP1401427A4 (fr) 2004-12-01
BR0210191A (pt) 2004-04-06
AU2002312348A1 (en) 2002-12-16
WO2002098363A2 (fr) 2002-12-12
EP1401427A2 (fr) 2004-03-31
MXPA03011002A (es) 2004-10-28
WO2002098363A3 (fr) 2003-03-20

Similar Documents

Publication Publication Date Title
JP7066768B2 (ja) 細胞内カルシウムを調節する化合物
US6833372B2 (en) Non-peptide GnRH agents, Pharmaceutical compositions, and methods for their use
EP1105120B1 (fr) Agents non peptidiques de l'hormone de liberation de la gonadotrophine et intermediaires utiles pour les preparer
TWI392673B (zh) 調控細胞內鈣離子濃度之化合物
JP2024045124A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
US20050250846A1 (en) Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
CN102883607A (zh) 用于治疗癌的化合物
JP2005501006A (ja) 非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法
CZ302896A3 (en) Condensed bicyclic thiophenone compound, process of its preparation, its use, antagonistic preparation, conception control preparation and menorrhoeal cycle control preparation
US7101878B1 (en) Non-peptide GNRH agents, methods and intermediates for their preparation
KR20080110905A (ko) 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도
TW200524924A (en) ATM inhibitors
CN103442566A (zh) 治疗癌症的化合物
SK11572000A3 (sk) Benzotiadiazoly a ich deriváty, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US20040010033A1 (en) Non-peptide GnRH agents, methods and intermediates for their preparation
WO2010082044A1 (fr) Dérivés hétérocycliques bicycliques insaturés utilisés comme antagonistes de smo
CN100429214C (zh) 1-氮杂-2-氧杂-二苯并[e,h]薁的制备以及它们用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
MXPA01001834A (en) NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
CZ290723B6 (cs) Kondenzované bicyklické thiofenové deriváty, způsob jejich výroby, farmaceutický prostředek je obsahující a jejich pouľití

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060831